hUC-MSC
/ Shenzhen Wingor Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 30, 2025
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: Shenzhen Wingor Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Ischemic stroke
July 25, 2025
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: Shenzhen Wingor Biotechnology Co., Ltd.
New P2 trial • Cardiovascular • Ischemic stroke
1 to 2
Of
2
Go to page
1